Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response

Diabetologia

Volumn 60, Issue 7, 2017, Pages 1276-1283

  Tavira, Beatriz ^a   Cheramy, Mikael ^a   Axelsson, Stina ^a   Åkerman, Linda ^a   Ludvigsson, Johnny ^a   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Children; GAD; H1N1; Immune intervention; Type 1 diabetes; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; C PEPTIDE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR NECROSIS FACTOR; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; AUTOANTIBODY; CYTOKINE; GLUTAMATE DECARBOXYLASE; HEMAGGLUTININ; INSULIN;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIET RESTRICTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SECONDARY ANALYSIS; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FINLAND; IMMUNE SYSTEM; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MULTICENTER STUDY; NORMAL DISTRIBUTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS); SWEDEN; TIME FACTOR; VACCINATION; YOUNG ADULT;

ADOLESCENT; ALUM COMPOUNDS; AUTOANTIBODIES; C-PEPTIDE; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; FINLAND; GLUTAMATE DECARBOXYLASE; HEMAGGLUTININS; HUMANS; IMMUNE SYSTEM; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INSULIN; MALE; NORMAL DISTRIBUTION; SWEDEN; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 85016410136     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4263-x     Document Type: Article

References (21)

1. Ludvigsson J (2016) The clinical potential of low-level C-peptide secretion. Expert Rev Mol Diagn 16:933–940
2. Schloot NC, Meierhoff G, Lengyel C et al (2007) Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind Phase II trials. Diabetes Metab Res Rev 23:276–285
3. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608
4. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692–1698
5. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152
6. Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378:412–419
7. Pozzilli P, Pitocco D, Visalli N et al (2000) No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB group. Diabetologia 43:1000–1004
8. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R, NBI-6024 Study Group (2009) No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32:2036–2040
9. Ludvigsson J, Hjorth M, Cheramy M et al (2011) Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 54:634–640
10. Ludvigsson J, Faresjo M, Hjorth M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909–1920
11. Ludvigsson J, Krisky D, Casas R et al (2012) GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366:433–442
12. Salinthone S, Kerns AR, Tsang V, Carr DW (2013) α-tocopherol (vitamin E) stimulates cyclic AMP production in human peripheral mononuclear cells and alters immune function. Mol Immunol 53:173–178
13. Morel S, Didierlaurent A, Bourguignon P et al (2011) Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461–2473
14. Ahmed SS, Schur PH, MacDonald NE, Steinman L (2014) Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 50:1–11
15. Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R (2013) Cellular and humoral immune responses in type 1 diabetic patients participating in a Phase III GAD-alum intervention trial. Diabetes Care 36:3418–3424
16. Axelsson S, Chéramy M, Hjorth M et al (2011) Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS One 6:e29008
17. Svensson M, Ramelius A, Nilsson AL et al (2014) Antibodies to influenza virus A/H1N1 hemagglutinin in type 1 diabetes children diagnosed before, during and after the SWEDISH A(H1N1)pdm09 vaccination campaign 2009-2010. Scand J Immunol 79:137–148
18. Brooking H, Ananieva-Jordanova R, Arnold C et al (2003) A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 331:55–59
19. Ludvigsson J, Chéramy M, Axelsson S, Pihl M, Akerman L, Casas R (2014) GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months. Diabetes Metab Res Rev 30:405–414
20. Galson JD, Trück J, Kelly DF, van der Most (2016) Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination. Sci Rep 6:37229
21. Leroux-Roels G, Marchant A, Levy J et al (2016) Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a Phase II, randomized, multicenter trial. Clin Immunol 169:16–27